Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: A marker of disease prognosis?

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1013-1021

  Sieglová, Zuzana ^a   Žilovcová, Soňa ^a   Čermák, Jaroslav ^a   Říhová, Hana ^a   Březinová, Dagmar ^a   Dvořáková, Renáta ^a   Marková, Markéta ^a   Maaloufová, Jacqueline ^a   Sajdová, Jana ^a   Březinová, Jana ^b   Zemanová, Zuzana ^b   Michalová, Kyra ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

acute myelogenous leukemia; Acute myeloid leukemia; AML; basepair, kilobasepair; BM; bone marrow; bp, kbp; Chromosomal aberrations; complete remission; CR; FAB; Genome instability; IPSS risk groups; Myelodysplastic syndromes; Prognosis of MDS; Telomere erosion

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME SIZE; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; GENETIC HETEROGENEITY; GENETIC STABILITY; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCHOOL CHILD; STRUCTURAL CHROMOSOME ABERRATION; TELOMERE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; GENOMIC INSTABILITY; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 3843080730     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.020     Document Type: Article

References (32)

1. Dhaene K., Van Marck E., Parwaresch R. Telomeres, telomerase and cancer: an up-date. Virchows Arch. 437:2000;1-16
2. Shay J.W., Werbin H., Wright W.E. Telomeres and telomerase in human leukemias. Leukemia. 10:1996;1255-1261
3. Blasco M.A. Telomeres and cancer: a tale with many endings. Curr Opin Genet Dev. 13:2003;70-76
4. Wu X., Zhu C.I., Zhao H., Grossman B.H., Shay J.W., Luo S., et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 95:2003;1211-1218
5. Franco S., Ozkaynak M.F., Sandoval C., Tugal O., Jayabose S., Engelhardt M., et al. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia. 17:2003;401-410
6. Lee J.J., Nam C.E., Cho S.H., Park K.S., Chung I.J., Kim H.J. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol. 82:2003;492-495
7. Yokota T., Suda T., Igarashi M., Kuroiwa T., Waguri A., Kawai H., et al. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer. 98:2003;110-118
8. Rosenberg R., Gertler R., Stricker D., Lassman S., Werner M., Nekarda H., et al. Telomere length and hTERT expression in patients with colorectal carcinoma. Recent Results Cancer Res. 162:2003;177-181
9. Iwama H., Tauchi T., Ohyashiki K., Ohyashiki J.H., Hayashi S., Hayashi S., et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet. 102:1998;397-402
10. Shay J.W., Wright W.E., Werbin H. Defining the molecular mechanism of human cell immortalization. Biochim. Biophys. Acta. 1072:1991;1-7
11. Shay J.W., Zou Y., Hiyama E., Wright W.E. Telomerase and cancer. Hum Mol Genet. 10:2001;677-685
12. Helder M.N., Wisman G.B., van der Zee A.G.J. Telomerase and telomeres: from basic biology to cancer treatment. Cancer Invest. 20:2002;82-101
13. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndrome. Br J Haematol. 51:1982;189-199
14. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Hematol J. 1:2000;53-66
15. Greenberg P., Cox Ch., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088
16. Boultwood J., Fidler C., Kusec R., Rack K., Elliot P.J., Atoyebi O., et al. Telomere length in myelodysplastic syndromes. Am. J. Hematol. 56:1997;266-271
17. Mittelmann F, editors. ISCN an International System for Human Cytogenetics Nomenclature. Basel: S Karger; 1995.
18. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 21:2002;680-687
19. Ohyashiki J.H., Ohyashiki K., Fujimura T., Kawakubo K., Shimamoto T., Iwabuchi A., et al. Telomere shortening associated with disease evolution pattern in myelodysplastic syndromes. Cancer Res. 54:1994;3557-3560
20. Engelhardt M., Ozkaynak M.F., Drullinsky P., Sandoval C., Tugal O., Jayabose S., et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 12:1998;13-24
21. Engelhardt M., Albanell J., Drullinsky P., Han W., Guillem J., Scher H.I., et al. Relative contribution of normal and neoplastic cells determine telomerase activity and telomere length in primary cancers of prostate, colon, and sarcoma. Clin Cancer Res. 10:1997;1849-1857
22. Leber B., Bacchetti S. Telomeres and telomerase in normal and malignant heamatologic cells. Leukemia Lymphoma. 24:1996;1-9
23. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., Moore M.A.S. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 90:1997;182-193
24. Counter C.M., Gupra J., Hurley C.B., Leber B., Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85:1995;2315-2320
25. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W., et al. Telomere stability is frequently impaired in high groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 5:1999;1155-1160
26. Říhová H., Dvořáková R., Žilovcová S., Březinová D., Čermák J., Sajdová J., et al. The level of telomerase activity in pre-leukemic and leukemic cells - a prospective prognostic marker of hematological malignancies. Hematol J. 3(Suppl 1):2002;197
27. Krsková-Honzátková L., Čermák J., Sajdová J., Starý J., Sedláček P., Sieglová Z. Microsatellite instability in hematological malignancies. Leukemia Lymphoma. 43:2001;1979-1986
28. Ohyashiki K., Iwama H., Yahata N., Tauchi T., Kawakubo K., Shimamoto T., et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leukemia Lymphoma. 423:2001;291-299
29. Johansson B., Mertens F., Mitelman F. Primary vs. secondary neoplasia-associated chromosomal abnormalities - balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer. 16:1996;155-163
30. Slugboom P.E., Droog S., Boomsma G.I. Genetic determination of telomere size in humans: a twin study of three age groups. Am. J. Hum. Genet. 52:1993;661-667
31. Krsková-Honzátková L., Čermák J., Sajdová J., Starý J., Sedláček P., Sieglová Z. Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes. Leukemia Res. 25:2001;45-53
32. Baur J.A., Zou Y., Shay J.W., Wright W.E. Telomere position effect in human cells. Science. 292:2001;2075-2077